Find Your Fit: 4 New Additions to the Belkin SoundForm Audio Collection Announced at IFA 2024
5.9.2024 10:00:00 CEST | Business Wire | Press release
SoundForm offers more options for premium features at accessible price points Belkin International at Exhibit Hall 3.2, stand #210
Belkin, a leading consumer electronics brand for over 40 years, today announced 4 new products across its SoundForm audio category, underscoring Belkin innovation, quality and its commitment to building products more responsibly. Belkin International can be found on the IFA show floor, Exhibit Hall 3.2, stand #210.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240905446437/en/
Belkin announces new SoundForm portfolio at IFA 2024 (Photo: Business Wire)
Designed in its in-house labs at Belkin Global Headquarters in California, every SoundForm product undergoes 150 meticulous quality tests, ensuring perfection before it reaches consumer’s ears. Design, sound quality, comfort, voice-calling performance, enhanced features and value are all considered with each new addition to the SoundForm portfolio.
Belkin Signature Sound is integrated throughout the SoundForm range. Developed by Belkin sound engineers, it allows the wearer to listen to music exactly the way the artist intended. Deep bass is balanced, vocals are crystal-clear, and treble is crisp. To do this, Belkin sound engineers test headphone and earphone frequency response and distortion, passive noise isolation, Environmental Noise Cancellation (ENC), Active Noise Cancellation (ANC) performance, and Sound Pressure Level (SPL) to ensure proper 98db output for ‘adult’ products and 85db ‘safe sound’ for ‘kids’ products—and more. All new SoundForm products feature ENC for voice isolating clear call quality as standard.
Consumers will find a product in the SoundForm collection to suit their needs–all without breaking the bank.
SoundForm Rhythm
The SoundForm Rhythm earbuds pack a punch while taking up minimal space. They were designed for consumers looking for a casual pair of earbuds for entertainment, work/study purposes, or daily use.
Features:
- Design: True wireless, stem-shaped
- Sound: 6mm drivers
- Battery life: 8 hours with an additional 20 hours of battery life in charging case; 10 minutes of charge gets 90 minutes of playtime
- Connection: Bluetooth 5.3 and Multipoint
- Included in package: USB-C fast charging compatible case
- Built with recycled plastics and packaged in 100% plastic-free packaging
- 2-year warranty
Price: $34.99 / £24.99 / €29.99
Availability: SoundForm Rhythm is available now on belkin.com and select retailers worldwide
SoundForm ClearFit
Get a (good) grip with the SoundForm ClearFit. When it’s time to move, ClearFit is a go-to. Perfect for sports, outdoor activities and workouts, these earbuds stay comfortably secured around the outer ear for great sound while allowing the user to stay aware of their surroundings.
Features:
- Design: Open-ear, secure, comfortable and IPx5 sweat resistant
- Sound: 14.2mm drivers
- Battery life: 8 hours with an additional 18 hours of battery life in charging case; 10 minutes of charge gets 90 minutes of playtime
- Connection: Bluetooth 5.3 and Multipoint
- Included in package: USB-C fast charging compatible case
- Built with recycled plastics and packaged in 100% plastic-free packaging
- 2-year warranty
Price: $59.99 / £39.99 / €49.99
Availability: SoundForm ClearFit is available now on belkin.com/de and belkin.com/uk and select retailers worldwide
SoundForm Isolate
The SoundForm Isolate is the first over-ear headphone with ANC by Belkin. Made for the modern and stylish individual, Isolate provides quality ANC at a reasonable price point. In addition to ANC, Isolate also has a built-in “Relaxation” track that plays on a loop for moments where you need to further tune out external noise. They come with a long battery life of 60 hours, 3 settings (Standard Listening, Active Noise Cancellation, Hear Thru Mode) and Bluetooth multipoint – all in a sleek and portable design.
Features:
- Design: Over-ear, foldable, extendable and comfortable with 5 mics and intuitive touch controls to easily manage sound with a tap
- Sound: 40mm drivers
- Battery life: 60 hours of battery life (40 hours with ANC on)
- Connection: Bluetooth 5.4 and Multipoint
- Included in package: USB-C charging and audio cable; 3.5mm audio cable for users that prefer wired connection
- Built with recycled plastics and packaged in 100% plastic-free packaging
- 2-year warranty
Price: $59.99 / £49.99 / €59.99
Availability: SoundForm Isolate will be available from Autumn 2024
SoundForm Surround
The SoundForm Surround over-ear headphones are perfect for when you need to chat on the go. ENC ensures clear calls with background noise kept to a whisper. Its foldable, extendable, and comfortable over-ear design and intuitive touch controls make SoundForm Surround an everyday accessory.
Features:
- Design: Over-ear, foldable, extendable and comfortable with intuitive touch controls to easily manage sound with a tap
- Sound: 40mm drivers
- Battery life: 60 hours
- Connection: Bluetooth 5.4 and Multipoint
- Included in package: USB-C charging and audio cable; 3.5mm audio cable for users that prefer wired connection
- Built with recycled plastics and packaged in 100% plastic-free packaging
- 2-year warranty
Price: $39.99 / £29.99 / €39.99
Availability: SoundForm Surround will be available from Autumn 2024
All new products are made with post-consumer recycled (PCR) plastics in line with the company’s commitment to find more responsible ways to build products. They will be on display at IFA 2024.
Media kit is available for download HERE.
About Belkin
Belkin is a California-based accessories leader delivering award-winning power, protection, productivity, connectivity, and audio products over the last 40 years. Designed and engineered in Southern California and sold in more than 100 countries around the world, Belkin has maintained its steadfast focus on research and development, community, education, sustainability and most importantly, the people it serves. From our humble beginnings in a Southern California garage in 1983, Belkin has become a diverse, global technology company. We remain forever inspired by the planet we live on, and the connection between people and technology.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240905446437/en/
Contacts
For Media Inquiries:
For Media Inquiries:
Jen Wei
VP of Global Communications and Corporate Development
Comms@belkin.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom